Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity

/PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat...

Related Keywords

China ,Australia ,New Zealand ,Hangzhou ,Zhejiang ,Chinese ,Sciwind Biosciences ,Thai Pan ,Prnewswire Sciwind Biosciences Co Ltd , ,Hangzhou Sciwind Biosciences Co ,Td ,